← All candidates
Three insider buys in the last year — $15.00M in all.
35 filings on record.
NMRANeumora Therapeutics, Inc.
NasdaqGS · Healthcare · $145.28M
$0.7732
-6.96% · Sep 16
Three insider buys in the last year — $15.00M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 3 buys● 16 sells◆ 5 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$145.28M
Float
116.4M
62% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
10% owner
Burow Kristina
Bought $5.00M on Oct 27 — 1,915,700 sh @ $2.61, held indirect, 32% of their stake.
0 of 1 position beat the S&P
10% owner
ARCH Venture Partners XII, LLC
Bought $5.00M on Oct 27 — 1,915,700 sh @ $2.61, held indirect, 32% of their stake.
0 of 2 positions beat the S&P
10% owner
ARCH Venture Partners X, LLC
Bought $5.00M on Oct 27 — 1,915,700 sh @ $2.61, held indirect, 32% of their stake.
0 of 2 positions beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
30 more transactions on Pro →Context
Wall St
$6.53 avg target
+744.9% vs today · 8 analysts · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$0.30 act+$0.01
Q4 '25−$0.35 act−$0.02
Q3 '25−$0.35 act−$0.01
Q2 '25−$0.33 act+$0.04
Coverage
Three pivotal MDD trial failures for Neumora lead to staffing cutsClinical Trials Arena · 06-16Neumora Stock Plunges 49% After Late-Stage Depression Drug FailureZacks · 06-16Neumora depression drug fails; EnGene to cut 50% of staffBioPharma Dive · 06-16NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage TrialsStocktwits · 06-15
The file stays open
35 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice